{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Precigen, Inc."},"Symbol":{"label":"Symbol","value":"PGEN"},"Address":{"label":"Address","value":"20374 SENECA MEADOWS PARKWAY, GERMANTOWN, Maryland, 20876, United States"},"Phone":{"label":"Phone","value":"+1 301 556-9900"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals; Exemplar, and Trans Ova. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs."},"CompanyUrl":{"label":"Company Url","value":"http://www.precigen.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Amy R. Lankford","title":"SVP, Head-Clinical Operations & Regulatory Affairs"},{"name":"Helen Sabzevari","title":"President, Chief Executive Officer & Director"},{"name":"Rutul R. Shah","title":"Chief Operating Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}